Concepedia

Marlene Biehl

MB

6

Publications

165

Citations

6

H-Index

2013

Active since

Affiliations

Roche (Switzerland)(Current)

Lonza (Switzerland)

Centro de Investigación Biomédica en Red de Cáncer

University of Zurich

Inserm

Marlene Biehl is an author at Roche (Switzerland) specializing in cancer research, cell signaling, and cell biology.

ORCID

Top concepts

Publications per year

2013–2024

6

Publications

6

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity

Johannes Sam, Sara Colombetti, Tanja Fauti et al. · Frontiers in Oncology · 2020 · 51 citations · Full text

Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies

Gabrielle Leclercq-Cohen, Nathalie Steinhoff, Llucia Albertí Servera et al. · Clinical Cancer Research · 2023 · 38 citations · Full text

Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines

Susanne Hartmann, N. Günther, Marlene Biehl et al. · Cancer Letters · 2013 · 24 citations

, , +9

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma

Jan Eckmann, Tanja Fauti, Marlene Biehl et al. · Blood · 2024 · 22 citations · Full text

Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response

Sami Akhras, Masako Toda, Klaus Böller et al. · Scientific Reports · 2017 · 16 citations · Full text

Rows per page

1–5 of 6